ArticleBiotechnology notes (Amsterdam, Netherlands)2022
Synthetic biology landscape and community in Germany.
Article in Biotechnology notes (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Governing Synthetic Biology: A Co-Evolutionary Framework for Sustainable Innovation.Journal of microbiology and biotechnology · 2025Review
- Engineered microbial consortia for next-generation feedstocks.Biotechnology notes (Amsterdam, Netherlands) · 2024Article
- Organ-on-chip technology: Opportunities and challenges.Biotechnology notes (Amsterdam, Netherlands) · 2024Review
- Synthetic biology in Indonesia: Potential and projection in a country with mega biodiversity.Biotechnology notes (Amsterdam, Netherlands) · 2023Review
- Building the SynBio community in the Czech Republic from the bottom up: You get what you give.Biotechnology notes (Amsterdam, Netherlands) · 2022Article
- Synthetic biology in Europe: current community landscape and future perspectives.Biotechnology notes (Amsterdam, Netherlands) · 2022Article
- A SynBio community comes of age: Political, academical, industrial, and societal developments in the Netherlands.Biotechnology notes (Amsterdam, Netherlands) · 2022Article
- Synthetic biology landscape in the UK.Biotechnology notes (Amsterdam, Netherlands) · 2022Article
- De novo synthesis of synthetic biology ecosystem in Slovakia: Challenges and opportunities.Biotechnology notes (Amsterdam, Netherlands) · 2022Article
- Bioeconomy in India: Policy, Prospects and Perspective.Engineering biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite its start in the early 2000s, synthetic biology is still overall perceived as a young discipline. In some countries, such as the US, synthetic biology is academically and industrially established, while in others, including Germany, it is still an upcoming field of research. Issues with funding schemes, commercial translation of technologies, public perception, and regulations need to be addressed to establish synthetic biology as a key discipline of the 21
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.